two first PCSK9 inhibitors (evolocumab - Repatha, Amgen, and alirocumab – Praluent, Sanofi) have been approved worldwide by both Food and Drug Administration (FDA) as well as European Medicine Agency (EMA) for the treatment of uncontrolled LDL-C levels in...
various lipid-based therapies have been advocated for the modulation of corneal diseases; however, the number of studies is still very limited. Here we focus on developments and challenges on lipid-based therapies for dry eye disease, diabetic neuropathy...